runimotamab

{
  "id": "MLC-T-ONC-016601",
  "term": "runimotamab",
  "field": "Oncology and biomedicine",
  "definition": "An anti-human epidermal growth factor receptor 2 (HER2)/anti-CD3 T-cell-dependent bispecific (TDB) monoclonal antibody with potential immunostimulatory and antineoplastic activities. Upon administration, runimotamab possesses two antigen recognition sites, one for HER2, a tyrosine kinase receptor overexpressed by many cancer cell types, and one for the CD3 complex, a group of T-cell surface glycoproteins that interact with the T-cell receptor (TCR). Upon administration of runimotamab, this bispecific monoclonal antibody simultaneously binds to both CD3-expressing T cells and HER2-expressing cancer cells, thereby crosslinking HER2-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This may result in potent CTL-mediated lysis of HER2-expressing tumor cells. HER2 plays a key role in tumor cell proliferation and tumor vascularization.",
  "synonyms": [
    "anti-HER2 x anti-CD3 bispecific monoclonal antibody BTRC 4017A",
    "anti-HER2 x anti-CD3 bispecific monoclonal antibody RG 6194",
    "BTRC-4017A",
    "anti-HER2/Anti-CD3 bispecific monoclonal antibody BTRC 4017A",
    "anti-HER2/anti-CD3 bispecific monoclonal antibody 4017A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/runimotamab/"
}